Raymond James Financial
AVXL icon

Raymond James Financial’s Anavex Life Sciences AVXL Stock Holding History

Raymond James Financial’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.9K Buy
22,433
+5,777
+35% +$25K ﹤0.01% 5089
2025
Q4 		$59.3K Sell
16,656
-5,289
-24% -$32.4K ﹤0.01% 4992
2025
Q3 		$195K Sell
21,945
-185
-0.8% -$1.88K ﹤0.01% 4630
2025
Q2 		$204K Buy
22,130
+5,000
+29% +$42.7K ﹤0.01% 4504
2025
Q1 		$147K Buy
17,130
+1,546
+10% +$14.6K ﹤0.01% 4483
2024
Q4 		$167K Buy
+15,584
New +$120K ﹤0.01% 4445

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Raymond James Financial's AVXL Position: Q1 2026 in Review

Raymond James Financial increased its Anavex Life Sciences (AVXL) stake by 35% in Q1 2026, buying an estimated $25K and bringing the position to 22,433 shares worth $68.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5089.

Raymond James Financial first reported a position in AVXL in Q4 2024 and has held it in 6 quarters since. The position peaked at $204K in Q2 2025. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Raymond James Financial held 22,433 shares of Anavex Life Sciences worth $68.9K as of Q1 2026.
  • Raymond James Financial bought 5,777 Anavex Life Sciences shares in Q1 2026, an estimated $25K.
  • Anavex Life Sciences made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5089 holding.
  • Raymond James Financial first reported a position in Anavex Life Sciences in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Anavex Life Sciences position peaked at $204K in Q2 2025.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.